CDK4 and cholangiocarcinoma: Acquired vulnerability screening in CCA clones under CDK4/6 inhibitor treatment revealed that while attempting to survive and proliferate under CDK4/6 inhibition, CCA cells alter their ribosomal balance, which results in a novel drugable weakness.